A registrational study of INCA 33890 in MSS colorectal cancer
Latest Information Update: 18 Nov 2025
At a glance
- Drugs INCA 33890 (Primary)
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Incyte Corporation
Most Recent Events
- 18 Nov 2025 New trial record
- 19 Oct 2025 According to Incyte corporation media release, Incyte plans to initiate a registrational program for INCA33890 in MSS colorectal cancer in 2026.